AzTrials
AzTrials

HealthyNCT02801643

The Impact of Reward-induced Dopamine Release on Functional Connectivity: a Combined PET/fMRI Study

An observational study of Healthy, run by Stony Brook University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The present study would be the first to investigate the relationship between reward- and or social stimuli-induced dopamine (DA) release and neural function using a combined PET/fMRI approach. Read more about this study

Who is it for?
Ages 18 to 45 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
How many people
5 participants
Where
1 siteUnited States
Study dates
Jun 2016to Dec 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: 20 subjects (ages 18-45 years) will be included. Male and female representation will be about equal. No ethnic/racial/gender group is excluded.

Who may be able to join

  • Healthy men and women age 18-45 who have the capacity to consent to the protocol.
  • Ability to understand and follow instructions and oriented to name, time, and place.
  • A negative urine pregnancy and toxicology screen
  • Willingness to abstain from using aspirin, NSAIDs, or anticoagulants during the study

Who cannot join

  • Left-handed or ambidextrous
  • History of seizures
  • History of strokes
  • Clinically significant, uncontrolled liver, kidney, cardiac, or pulmonary disease
  • Terminal medical diagnosis consistent with survival < 1 year
  • Serious mental impairment. Mini mental state exam of < 23/30
Show all 18Show fewer
  • Current or past DSM-IV Axis I or neurologic disorders
  • Actively abusing substances, including alcohol (regular alcohol use during the past 6 months equal to or greater than 16 cans of beer per week or equivalent; use of street drugs or regular tobacco use during the past 6 months)
  • Unstable medical condition (≥ 3 months), or serious medical illnesses during the past three months (e.g., serious infections)
  • Unexplained loss of consciousness; history of traumatic brain injury involving loss of consciousness greater than 2 minutes
  • Currently pregnant or breastfeeding, sexually active and of child-bearing potential and not using adequate contraceptive methods
  • Childbirth or miscarriage during past 6 months, breastfeeding within 6 months of recruitment
  • Allergic to latex and/or study pharmaceuticals
  • Diabetes and/or unable to fast for up to 7 hours
  • Unable to lie comfortably in the scanner for up to 4 consecutive hours
  • Would receive a total of over 5 rems to a radiosensitive organ (bone marrow, gonads, lens of the eye) or 15 rems to any other organ or to the body as a whole during a 12 month period
  • Contraindications for MRI including neurostimulators, implanted medical devices, metal in the body, claustrophobia, weight over 440 pounds, and girth size incompatible for scanner bore.
  • Participation in a similar Social Feedback Task within 2 months of the start of the study.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Health Sciences Center

    Stony Brook, New York, 11794

Other trials in United States

About this study

The present study would be the first to investigate the relationship between reward- and or social stimuli-induced dopamine (DA) release and neural function using a combined PET/fMRI approach. Data from this project conducted in healthy subjects will provide preliminary data for a larger grant application to study patient populations with known abnormalities in DA including schizophrenia, major depressive, substance use, and eating disorders.

Read the detailed description

Aim 1. To test the relationship between reward-induced dopamine (DA) release on changes in resting state functional connectivity (RSFC) in healthy subjects. In 20 healthy adults, the investigators will examine DA release (measured using positron emission tomography, PET) in the ventral striatum, thalamus, and prefrontal cortex, as previously described. Before and after the task the investigators will examine RSFC (measured using functional magnetic resonance imaging, fMRI) between these structures, which have been shown to form functional pathways serving motivation and emotion regulation in rodents and nonhuman primates. The investigators hypothesize that DA release will impact the functional relationship between these and other structures as determined by changes in RSFC.

Aim 2. To examine the relationship between dopamine release and the Reward Positivity (RewP) potential. Subjects will be presented with the option to participate in an event-related potential (ERP) study. The investigators will correlate the amount of DA release with the amplitude of the RewP potential, an ERP that is enhanced in reward versus non-reward circumstances. Based on previous studies, the investigators hypothesize that RewP amplitude will positively correlate with dopamine release in the nucleus accumbens.

Conditions
Healthy
Keywords
PET, dopamine, fMRI, reward

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dopamine receptor binding potential

    changes in dopamine receptor binding potential will be measured during and after a reward task or social stimulus task

    Measured: 1-3 weeks

  2. Resting state fMRI

    Resting state functional connectivity will be measured using fMRI

    Measured: 1-3 weeks

  3. Event-related potential (ERP) during reward

    ERP during a reward task is measured

    Measured: 1-3 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Jun 2016 (estimated)
  2. Study startJun 2016
  3. Primary completionDec 2017
  4. Study completionDec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
5 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02801643
Sponsor's protocol ID
PET/MR Pilot
Status last verified
Apr 2018
First submitted
13 Jun 2016
Last updated
17 Apr 2018
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Healthy, run by Stony Brook University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Apr 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Dopamine receptor binding potential (time frame: 1-3 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in